PIK3CA and non-small cell lung carcinoma: Together, our findings highlighted an intriguing molecular feature and potential therapeutic target for combination therapies targeting the FGFR and PI3K pathways in FGFR-positive NSCLC patients exhibiting activated PI3K and MAPK pathways.